Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Fda Approves Agile Therapeutics Inc S Twirla Levonorgestrel And Ethinyl Estradiol Transdermal System A New Weekly Contraceptive Patch Delivering A 30 Mcg Daily Dose Of Estrogen And 120 Mcg Daily Dose Of Progestin is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc ... s sustainability in 2023 by once again demonstrating meaningful year-over-year growth in net revenue, Twirla ... Read More
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call Transcript
Agile Therapeutics, Inc ... of today's call, we will refer to certain non-GAAP financial measures. A reconciliation of GAAP to non-GAAP measures is included in our press release issued today ... Read More
Agile Therapeutics Announces Delisting from Nasdaq
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq ... that have the ability to maximize Twirla growth, as well as grow shareholder value. Following the Nasdaq ... Read More
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
In an exploratory analysis, an improvement of central nervous system ... FDA collaborated with the Australian Therapeutics Goods Administration (TGA), Health Canada (HC), Israel's Ministry ... Read More
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's ... this press release are reported as of December 31, 2023, by Symphony Health Solutions. The ... Read More
Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
Good morning, and welcome to the Agile Therapeutics ... s call, we will refer to certain non-GAAP financial measures. A reconciliation of GAAP to non-GAAP measures is included in our press release ... Read More
Agile Therapeutics Announces Delisting from Nasdaq
About Agile Therapeutics, Inc ... Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal ... Read More
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and ... 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company ... Read More
Agile Therapeutics, Inc.: Agile Therapeutics Announces Delisting from Nasdaq
About Agile Therapeutics, Inc ... Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal ... Read More
Agile Therapeutics, Inc.: Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla ... 30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus